Cargando…
ABT-737, a Bcl-2 family inhibitor, has a synergistic effect with apoptosis by inducing urothelial carcinoma cell necroptosis
ABT-737 is a recently reported inhibitor of members of the Bcl-2 family of apoptosis regulators. However, to the best of our knowledge, its necroptosis-inducing function in bladder cancer has not yet been researched. Thus, the present study aimed to investigate whether this Bcl-2 family inhibitor ca...
Autores principales: | Cheng, Rui, Liu, Xiaolong, Wang, Zheng, Tang, Kunlong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025475/ https://www.ncbi.nlm.nih.gov/pubmed/33786632 http://dx.doi.org/10.3892/mmr.2021.12051 |
Ejemplares similares
-
ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells
por: Yin, Pei, et al.
Publicado: (2016) -
Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022) -
The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders
por: Robert, Aude, et al.
Publicado: (2020) -
ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012) -
The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2016)